DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) - MARKET SIZE, PREVALENCE, INCIDENCE, QUALITY OUTCOMES, TOP HOSPITALS & PHYSICIANS
Want to know more about Dexur's Capabilities? Get In Touch
Jan 2013 to Dec 2017   |   Jan 2017 to Dec 2017
CHARGE CAPTURE ANALYSIS FOR DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) GROUP BASED ON MEDICARE | |
DEMOGRAPHIC DETAILS OF DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
Race |
Total Hospitalization Volume - Jan 2017 to Dec 2017 |
% of DRG Volume |
White |
15,186 |
81.12 |
Black |
2,387 |
12.75 |
Asian |
375 |
2.0 |
|
|
|
|
|
|
|
|
|
|
|
|
Age Group ( Years ) |
Total Hospitalization Volume - Jan 2017 to Dec 2017 |
% of DRG Volume |
70 to 74 |
4,011 |
21.43 |
65 to 69 |
3,786 |
20.22 |
75 to 79 |
3,452 |
18.44 |
|
|
|
|
|
|
|
|
|
TOP ICD DIAGNOSIS CODES FOR DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
TOP ICD PROCEDURE CODES FOR DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
TOP HOSPITALS ASSOCIATED WITH DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
TOP ATTENDING PHYSICIAN ASSOCIATED WITH DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
TOP OPERATING PHYSICIAN ASSOCIATED WITH DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
DRG 180: RESPIRATORY NEOPLASMS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) SUMMARY TABLE | |
Category |
Sub Category |
DRG Group |
ICD Codes |
ICD Description |
National Projected Hospitalizations (Present on Admission - All) Jan 2016 to Dec 2016 |
Medicare Hospitalizations (Present on Admission - All) Jan 2017 to Dec 2017 |
National Projected Hospitalizations(Present on Admission - Yes) Jan 2016 to Dec 2016 |
Medicare Hospitalizations (Present on Admission - Yes) Jan 2017 to Dec 2017 |
National Projected Hospitalizations (Present on Admission - Not Y) Jan 2016 to Dec 2016 |
Medicare Hospitalizations (Present on Admission - Not Y) Jan 2017 to Dec 2017 |
Total Discharges After Exclusion |
Avg. LOS |
GMLOS |
All Cause Readmission Rate (%) |
Unplanned Readmission Rate (%) |
Total Medicare Payments |
Payment per Day |
Payment per Discharge |
Total Medicare Charges |
Avg. Charges |
Mortality Rate (%) |
SNF Discharge Rate (%) |
Home Discharge Rate (%) |
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
Z87891 |
Personal history of nicotine dependence |
16,086 |
8,244 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
I10 |
Essential (primary) hypertension |
18,695 |
8,003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
Z66 |
Do not resuscitate |
13,311 |
7,326 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
E785 |
Hyperlipidemia, unspecified |
11,781 |
6,743 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
J189 |
Pneumonia, unspecified organism |
15,414 |
6,349 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
J910 |
Malignant pleural effusion |
11,759 |
6,335 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
Z515 |
Encounter for palliative care |
11,177 |
5,558 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
I2510 |
Atherosclerotic heart disease of native coronary artery without angina pectoris |
7,531 |
4,643 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
J449 |
Chronic obstructive pulmonary disease, unspecified |
10,408 |
4,465 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology & Hematology |
Respiratory Neoplasms |
Respiratory Neoplasms |
C3490 |
Malignant neoplasm of unspecified part of unspecified bronchus or lung |
10,620 |
4,365 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|